Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News CureVac NV CVAC

Healthcare Biotechnology
CureVac AG is a clinical-stage biopharmaceutical company, The Company strives to create transformative medicines to protect and improve people’s lives. Fueled by proprietary RNA technology platform combined with two decades of science and manufacturing, The Company is dedicated to creating novel treatments that enable the body to make its own prophylactic and therapeutic drugs.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:CVAC)

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update

Accesswire 1 day ago

CureVac Appoints Thaminda Ramanayake as New Chief Business Officer

Accesswire 1 day ago

CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK

Accesswire 1 day ago

CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024

Accesswire 7 days ago

CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines

Accesswire 9 days ago

CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK

Accesswire April 4, 2024

CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform

Accesswire January 5, 2024

CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE

Accesswire December 19, 2023

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update

Accesswire November 14, 2023
View More News ››

Opinion & Analysis (NDAQ:CVAC)

BioNTech, CureVac, Valeo Pharma - COVID-19 wakes up the industry

Stockhouse Editorial September 1, 2020
View More Opinion ››

Bullboard Posts (NDAQ:CVAC)

Strong Pre-Market $80s

It would be crazy if this would touch tripple digit today ....
ZER0C00L - August 17, 2020
View more Bullboard ››

Hank Payments Corp.

Hank Payments Corp.

Hank Payments Corp is an emerging North American leader in the Banking-as-a-Service (BaaS) market. The Hank platform ...
View More »